![Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f088fbaa-3134-4ce6-8294-01c8c23f249b/gr1.gif)
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet
![Adaptive designs in clinical trials: why use them, and how to run and report them | BMC Medicine | Full Text Adaptive designs in clinical trials: why use them, and how to run and report them | BMC Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12916-018-1017-7/MediaObjects/12916_2018_1017_Fig1_HTML.gif)
Adaptive designs in clinical trials: why use them, and how to run and report them | BMC Medicine | Full Text
![PDF] Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial | Semantic Scholar PDF] Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/60afa7902fddea770036d6744ee84027545bd238/3-Figure1-1.png)
PDF] Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial | Semantic Scholar
![Expired Breath Carbon Monoxide Levels in a 14Week Open-Label Trial of... | Download Scientific Diagram Expired Breath Carbon Monoxide Levels in a 14Week Open-Label Trial of... | Download Scientific Diagram](https://www.researchgate.net/profile/James-Gold-2/publication/12050357/figure/fig1/AS:601716932231173@1520471904467/Expired-Breath-Carbon-Monoxide-Levels-in-a-14Week-Open-Label-Trial-of-Supportive-Group.png)
Expired Breath Carbon Monoxide Levels in a 14Week Open-Label Trial of... | Download Scientific Diagram
![A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. | Semantic Scholar A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/657042084cf76b914d963e8982430b25f0d38edc/7-Table1-1.png)
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. | Semantic Scholar
![Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial - The Lancet Respiratory Medicine Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial - The Lancet Respiratory Medicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/965c25ef-f1a8-470d-9a67-7a6c66c86e2a/gr1.gif)
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial - The Lancet Respiratory Medicine
![Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study) - eClinicalMedicine Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study) - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/40b78dea-a1a9-4213-bee3-dc5db782df62/gr1.jpg)
Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study) - eClinicalMedicine
![Hydroxychloroquine for COVID-19: What do the clinical trials tell us? - The Centre for Evidence-Based Medicine Hydroxychloroquine for COVID-19: What do the clinical trials tell us? - The Centre for Evidence-Based Medicine](https://www.cebm.net/wp-content/uploads/2020/04/Jeff_Robin.jpg)
Hydroxychloroquine for COVID-19: What do the clinical trials tell us? - The Centre for Evidence-Based Medicine
PLOS ONE: A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)
![Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4ba8a139-a98a-4306-9ae7-443a9ad74d47/gr1_lrg.jpg)
Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - Annals of Oncology
![Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study | BMJ Open Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/6/2/e010313/F2.large.jpg)
Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study | BMJ Open
![Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - The Lancet Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2b0c5fe8-d7eb-4483-b185-176f340ad2b7/gr1.gif)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - The Lancet
PLOS ONE: Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial
![Adaptive platform trials: definition, design, conduct and reporting considerations | Nature Reviews Drug Discovery Adaptive platform trials: definition, design, conduct and reporting considerations | Nature Reviews Drug Discovery](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41573-019-0034-3/MediaObjects/41573_2019_34_Fig1_HTML.png)
Adaptive platform trials: definition, design, conduct and reporting considerations | Nature Reviews Drug Discovery
PLOS ONE: Why do open-label placebos work? A randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis
![Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open- label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open- label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2883e24f-ded5-4447-96b4-db02193741ca/gr1.gif)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open- label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology
![Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial | Scientific Reports Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-81502-2/MediaObjects/41598_2021_81502_Fig1_HTML.png)
Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial | Scientific Reports
![Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis - Clinical Gastroenterology and Hepatology Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis - Clinical Gastroenterology and Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/54056a92-9557-4021-97e3-96d78f9d719a/gr1.jpg)
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis - Clinical Gastroenterology and Hepatology
![Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial) Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)](https://bmjopen.bmj.com/content/bmjopen/5/12/e009562/F1.large.jpg)
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)
![How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download](https://images.slideplayer.com/23/6590870/slides/slide_3.jpg)